A Single-center Prospective Interventional Study on FPG500 in Non-metastatic Prostate Cancer Patients

Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Mar 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to understand and treat non-metastatic prostate cancer, which means the cancer has not spread to other parts of the body. Researchers at a leading Italian hospital are using advanced testing to look for specific changes in genes that could help predict how the cancer might grow or spread. This information could help doctors decide on the best treatment options for patients, especially those at high risk of their cancer becoming more aggressive. The goal is to identify those who might need more immediate treatment and to monitor patients who are being watched closely without treatment.

To be eligible for this study, participants must have a confirmed diagnosis of either low-risk or high-risk prostate cancer. This includes patients who are either being actively monitored or are scheduled for surgery. However, individuals with other cancers or those already receiving certain treatments for prostate cancer will not be included. Those who join the trial can expect to undergo genetic testing, which could lead to a better understanding of their cancer and more personalized treatment plans. Overall, the hope is to improve outcomes for patients by using this advanced genomic information.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • histologically proven diagnosis of low-risk, or high-risk or locally advanced prostate cancer
• • high-risk and locally advanced prostate cancer undergoing surgery
• • low-risk prostate cancer undergoing active surveillance or surgery
• Exclusion Criteria:
• • previous or concomitant malignancies
• • patients already undergoing androgen suppression or other medical treatments for prostate cancer